Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

642 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hepatitis C virus core antigen in the management of patients treated with new direct-acting antivirals.
Arboledas JCA, Guerrero IP, Rodríguez MJB, Martos ET, Pérez AB, León CC, Sierra Sánchez JF, Prieto MDL, Porcuna NC, Mochón MDO, Macías J, de la Iglesia Salgado A, Granger JR, Fernández MD, Lozano IG, Ramírez ER, Rivero A, Del Carmen Lozano Domínguez M, Viciana I, Montemayor JCG, García FG. Arboledas JCA, et al. Among authors: rivero a. Diagn Microbiol Infect Dis. 2017 Sep;89(1):29-34. doi: 10.1016/j.diagmicrobio.2017.06.006. Epub 2017 Jun 17. Diagn Microbiol Infect Dis. 2017. PMID: 28669680
Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C.
Macías J, Mira JA, López-Cortés LF, Santos I, Girón-González JA, González-Serrano M, Merino D, Hernández-Quero J, Rivero A, Merchante N, Trastoy M, Carrillo-Gómez R, Arizcorreta-Yarza A, Gómez-Mateos J, Pineda JA. Macías J, et al. Among authors: rivero a. Antivir Ther. 2006;11(7):839-46. Antivir Ther. 2006. PMID: 17302246
The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection.
Vergara S, Macías J, Rivero A, Gutiérrez-Valencia A, González-Serrano M, Merino D, Ríos MJ, García-García JA, Camacho A, López-Cortés L, Ruiz J, de la Torre J, Viciana P, Pineda JA; Grupo para el Estudio de las Hepatitis Viricas de la SAEI. Vergara S, et al. Among authors: rivero a. Clin Infect Dis. 2007 Oct 15;45(8):969-74. doi: 10.1086/521857. Epub 2007 Sep 11. Clin Infect Dis. 2007. PMID: 17879910
Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients.
Mira JA, López-Cortés LF, Merino D, Arizcorreta-Yarza A, Rivero A, Collado A, Ríos-Villegas MJ, González-Serrano M, Torres-Tortoso M, Macías J, Valera-Bestard B, Fernández-Fuertes E, Girón-González JA, Lozano F, Pineda JA; Grupo para el Estudio de las Hepatitis Viricas de la Sociedad Andaluza de Enfermedades Infecciosas. Mira JA, et al. Among authors: rivero a. Antivir Ther. 2007;12(8):1225-35. Antivir Ther. 2007. PMID: 18240862
Baseline serum low-density lipoprotein cholesterol levels predict response to hepatitis C virus therapy in HIV/hepatitis C virus coinfected patients.
del Valle J, Mira JA, de los Santos I, López-Cortés LF, Merino D, Rivero A, Girón JA, Ríos-Villegas MJ, González-Serrano M, Collado A, García-García JA, Pineda JA. del Valle J, et al. Among authors: rivero a. AIDS. 2008 May 11;22(8):923-30. doi: 10.1097/QAD.0b013e3282ff8ad3. AIDS. 2008. PMID: 18453851
Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone.
Mira JA, López-Cortés LF, Barreiro P, Tural C, Torres-Tortosa M, de Los Santos Gil I, Martín-Rico P, Ríos-Villegas MJ, Hernández-Burruezo JJ, Merino D, López-Ruz MA, Rivero A, Muñoz L, González-Serrano M, Collado A, Macías J, Viciana P, Soriano V, Pineda JA. Mira JA, et al. Among authors: rivero a. J Antimicrob Chemother. 2008 Dec;62(6):1365-73. doi: 10.1093/jac/dkn420. Epub 2008 Oct 13. J Antimicrob Chemother. 2008. PMID: 18854330 Clinical Trial.
Hepatic safety of tipranavir plus ritonavir (TPV/r)-based antiretroviral combinations: effect of hepatitis virus co-infection and pre-existing fibrosis.
Macías J, Orihuela F, Rivero A, Viciana P, Márquez M, Portilla J, Ríos MJ, Muñoz L, Pasquau J, Castaño MA, Abdel-Kader L, Pineda JA; Hepatip Study Group. Macías J, et al. Among authors: rivero a. J Antimicrob Chemother. 2009 Jan;63(1):178-83. doi: 10.1093/jac/dkn429. Epub 2008 Oct 24. J Antimicrob Chemother. 2009. PMID: 18952618
642 results